To record electrical activity of muscles of the stomatognathic system, especially temporalis, masseter and digastric
To clinically monitor up to eight different muscles as an aid in the diagnosis and treatments evaluation by recording the electrical activity of muscles of the stomatognathic system
To determine the degree of relaxation (intra-patient) of a single muscle / group of muscles at rest
To measure relative (intra-patient) levels of activity of several muscles during a functional act

Indications for Use: 2 channel JVA amplifier

To record and display sounds / vibrations from the temporomandibular joints
To aid the clinician in his analysis of a joint sound/vibration by allowing him/her to see the waveform in various standard plots (together with K981563)
To aid the clinician in comparing a patient's current stand plots to previous recordings before, during and after treatment
To provide numerical values that can be used to quantify the physical characteristics of the sounds / vibrations, allowing intra-patient comparisons (only) by the clinician

Device Description

The BioEMG III is a multi-channel electromyographic amplifier which includes; a) eight (8) identical high-gain differential input amplifiers, b) eight (8) identical opto-coupler isolation units and c) eight (8) ourput buffer amplifiers. The overall amplification of the BioEMG III is calibrated to 5000X. The bandwidth filtering is set (fixed) from 30 Hz to 1000 Hz (± 3 dB). The common mode rejection ratio is ≥ 130 dB at the power line frequency (50/60 Hz). The BioEMG III includes an isolated power converter that converts non-isolated +5 vdc into isolated + 5 and - 5 vdc. It may be connected to a personal computer through an analog to digital converter. Only three (3) functions are provided by the BioEMG III; I) amplification, 2) bandwidth limiting and 3) electrical isolation of the patient.

Analogous to the BioEMG II, the BioEMG III also incorporates two (2) additional inputs for recording vibrations from the left and right temporomandibular joints. They consist of: a) two (2) identical high-gain amplifiers and b) two (2) output buffer amplifiers. For these inputs no isolation is required because there is no electrical connection to the patient. The amplification is calibrated to 5000X and the bandwidth filtering is set from 30 Hz to 1000 Hz (± 3dB). These channels are also powered from an external +5 vdc non-isolated source, which is converted to +5 and -5 vdc. The vibration signals may also be connected to a personal computer through an analog to digital converter. The two (2) functions performed by these "JVA" channels include: 1) amplification and 2) bandwidth limiting.

AI/ML Overview

The provided text is a 510(k) summary for the BioEMG III device. It focuses on demonstrating substantial equivalence to a predicate device (BioEMG II) through technological characteristics and non-clinical test data. However, it does not contain information about acceptance criteria or a study that rigorously proves the device meets specific performance criteria in a clinical setting with human readers or a standalone algorithm.

Therefore, many of the requested sections (e.g., sample sizes, expert qualifications, HRMR studies, ground truth details) cannot be extracted from this document as it primarily addresses regulatory submission for substantial equivalence based on technical specifications.

Here's what can be extracted based on the provided text:

1. Table of Acceptance Criteria and Reported Device Performance

The document does not explicitly state formal "acceptance criteria" for clinical performance. Instead, it demonstrates performance by showing the BioEMG III retains the "same levels of amplification, isolation and band-pass filtering" as the predicate device (BioEMG II).

Characteristic	Acceptance Criteria (Implied: Same as BioEMG II)	Reported Device Performance (BioEMG III)
Overall Amplification	5000X	Calibrated to 5000X
Bandwidth Filtering (EMG)	30 Hz to 1000 Hz (± 3 dB)	Set (fixed) from 30 Hz to 1000 Hz (± 3 dB)
Common Mode Rejection Ratio (EMG)	≥ 130 dB at 50/60 Hz	≥ 130 dB at the power line frequency (50/60 Hz)
Bandwidth Filtering (JVA)	30 Hz to 1000 Hz (± 3dB)	Set from 30 Hz to 1000 Hz (± 3dB)
Isolation (EMG channels)	Electrical isolation of the patient	Electrical isolation of the patient

2. Sample size used for the test set and the data provenance

Sample Size: Not applicable/Not mentioned. The testing was non-clinical, using a function generator and oscilloscope.
Data Provenance: Not applicable/Not mentioned. The testing was described as non-clinical bench testing.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts

Number of Experts: Not applicable/Not mentioned. The "ground truth" was established purely through instrumental measurements against known calibration signals.

4. Adjudication method for the test set

Adjudication Method: Not applicable/Not mentioned. No human assessment or adjudication process was described for the non-clinical tests.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

MRMC Study: No. This device is an electromyograph and joint vibration amplifier, not an AI-powered diagnostic imaging tool. No MRMC study was conducted or mentioned.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

Standalone Performance: Not applicable. The device is a hardware amplifier; its performance is based on its electronic specifications (amplification, filtering, isolation) rather than algorithmic output. The non-clinical test data focused on these hardware characteristics.

7. The type of ground truth used

Ground Truth Type: Calibrated function generator signals and oscilloscope readings. This represents a technical "ground truth" for electrical signal processing.

8. The sample size for the training set

Training Set Sample Size: Not applicable. This device does not use machine learning or AI, so there is no "training set."

9. How the ground truth for the training set was established

Training Set Ground Truth: Not applicable. As there's no training set, this is not relevant.

Summary

{0}------------------------------------------------

Bi
RESEARCH
ASSOCIATES INC.

1082927

510(k) Summary

FEB - 6 2009

BioResearch Associates, Inc. 9275 North 49th Street Suite 150 Brown Deer. WI 53223 Ph: (414) 357-7525 Fax: (414) 357-7545 Official Correspondent: John Radke 15 September 2008

Trade Name: BioEMG III

Common Name: 8 channel electromyograph + 2 channel joint vibration amplifier

Classification Name: Diagnostic electromyograph (21 CFR 890.1375, Product Code KZM and NFQ

Equivalent Device: BioEMG II (K003176)

Product Description:

Intended Use for electromyography: (same as for BioEMG II - K003176)

1. To record electrical activity of muscles of the stomatognathic system, especially the temporalis, masseter and digastric
To clinically monitor up to eight different muscles as an aid in diagnosis and treatment evaluation by 2. recording the electrical activity of the muscles of the stomatognathic system

{1}------------------------------------------------

To determine the degree of relaxation (intra-patient) of a single muscle / group of muscles at rest 3.
1. To measure relative (intra-patient) levels of activity of several muscles during a functional act

Intended Use for joint vibration recording: (same as for BioEMG II - K003176)

1. To record and display sounds / vibrations from the temporomandibular joints
1. To aid the clinician in his analysis of a joint sound / vibration by allowing him/her to see the waveform in various standard plots
1. To aid the clinician in comparing a patient's current standard plots to previous recordings before, during and after treatment
1. To provide numerical values that can be used to quantify the physical characteristics of the sounds / vibrations, allowing intra-patient comparisons (only) by the clinician

Technological Characteristics:

The technological advantages of the BioEMG III (compared to the predicate device) include:

The use of surface-mount technology has reduced the BioEMG II 2-board design with intercomnections to a 1board design with higher theoretical reliability for the BioEMG III.
The elimination of the one mechanical switch (used to switch between EMG and JVA modes) on the PC board of the BioEMG II may reduce "wrong switch position operation."
A new "touchless" connector will allow activation of only the channels being electrical interference from unused channels. As an indicator for the operator, a separate LED for each channel will light up whenever a lead is "plugged all the way in," activating that channel.
Due to the use of newer, low-power electronic components the BioEMG III will use less energy than the predicate device. This change should (theoretically) allow the BioEMG III to maintain its calibration longer than previously possible.
The functional characteristics of the BioEMG III are identical to those of the BioEMG II (K003176). See Exhibit G.
New features of the BioEMG III include; a) shielded lead-wires to minimized noise pickup from cell phone transmissions and b) a reference (isolated ground) continuity test circuit.

Non-clinical Test Data:

Utilizing a calibrated function generator and oscilloscope we have applied test signals to both instruments. In exhibit E we have supplied comparable graphic plots of the frequency response characteristics of both instruments. In the BioEMG III it is clear that we have retained the same levels of amplification, isolation and band-pass filtering as used in the BioEMG II predicate device.

{2}------------------------------------------------

DEPARTMENT OF HEALTH & HUMAN SERVICES

Image /page/2/Picture/1 description: The image contains the words "Public Health Service" in a simple, sans-serif font. The text is arranged on a single line, with each word clearly legible. The overall impression is clean and straightforward, suggesting an official or institutional context.

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Bio-Research Associates, Inc. % Mr. John Radke 9275 N. 49th St. Brown Deer, Wisconsin 53223

6 2000

Re: K082927

Trade/Device Name: BioEMG III Regulation Number: 21 CFR 890.1375 Regulation Name: Diagnostic electromyograph Regulatory Class: Class II Product Code: KZM Dated: January 29, 2009 Received: January 29, 2009

Dear Mr. Radke:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good nianufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

{3}------------------------------------------------

Page 2 - Mr. John Radke

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at (240) 276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at toll-free number (800) 638-2041 or (240) 276-3150 or Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Mark N. Millerson

Mark N. Melkerson Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

Indications for Use

510(k) Number (if known): K082927

Device Name: BioEMG III

Indications for Use:

Indications for use: 8 channel EMG amplifier

To record electrical activity of muscles of the stomatognathic system, especially temporalis, masseter and digastric
To clinically monitor up to eight different muscles as an aid in the diagnosis and treatments evaluation by recording the electrical activity of muscles of the stomatognathic system
To determine the degree of relaxation (intra-patient) of a single muscle / group of muscles at rest
To measure relative (intra-patient) levels of activity of several muscles during a functional act

Indications for Use: 2 channel JVA amplifier

To record and display sounds / vibrations from the temporomandibular joints
To aid the clinician in his analysis of a joint sound/vibration by allowing him/her to see the waveform in various standard plots (together with K981563)
To aid the clinician in comparing a patient's current stand plots to previous recordings before, during and after treatment
To provide numerical values that can be used to quantify the physical characteristics of the sounds / vibrations, allowing intra-patient comparisons (only) by the clinician

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use Yes (Part 21 CFR 801 subpart D)

Over the counter use AND/ORI) (21 CFR 801 subpart D)

(Division Sign-Off) Division of General, REARFafive, and Neurological Devices

510(k) Number.

Regulation Number and Section

§ 890.1375 Diagnostic electromyograph.

(a)
Identification. A diagnostic electromyograph is a device intended for medical purposes, such as to monitor and display the bioelectric signals produced by muscles, to stimulate peripheral nerves, and to monitor and display the electrical activity produced by nerves, for the diagnosis and prognosis of neuromuscular disease.(b)
Classification. Class II (performance standards).